369,229 results match your criteria Lymphoproliferative Disorders


A Case Report of Subclinical Myasthenia Gravis Associated with Castleman's Disease.

Am J Case Rep 2021 Jun 11;22:e930948. Epub 2021 Jun 11.

Department of Thoracic Surgery, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

BACKGROUND Castleman's disease is defined as a benign lymphoproliferative disorder of uncertain origin. It is most commonly found in the area of mediastinum. Castleman's disease is classified based on pathological features into hyaline-vascular, plasma cell, and mixed variants, which the hyaline-vascular variant is the commonest in association with Myasthenia Gravis. Read More

View Article and Full-Text PDF

Use of rituximab in paediatric nephrology.

Arch Dis Child 2021 Jun 10. Epub 2021 Jun 10.

Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

Rituximab is a chimeric monoclonal antibody capable of depleting B cell populations by targeting the CD20 antigen expressed on the cell surface. Its use in oncology, initially in B cell lymphoma and post-transplant lymphoproliferative disorders, predates its current utility in various fields of medicine wherein it has become one of the safest and most effective antibody-based therapies. It was subsequently found to be effective for rheumatological conditions such as rheumatoid arthritis and antineutrophil cytoplasmic antibody-associated vasculitis. Read More

View Article and Full-Text PDF

Clinical features of NK/T-cell EBV-associated LPD manifested as gastrointestinal symptoms in patients with normal immunity: a case report and literature review.

BMC Gastroenterol 2021 Jun 10;21(1):254. Epub 2021 Jun 10.

Department of Gastroenterology, The Second Xiangya Hospital, Changsha, 410011, Hunan, China.

Background: Epstein-Barr virus (EBV)-associated NK/T-cell lymphoproliferative disorder (LPD) involving the gastrointestinal tract is rarely observed in individuals with normal immunity. The atypical clinical, colonoscopic manifestations often confuse clinicians, leading to misdiagnosis and delays in the treatment.

Case Presentation: Herein, we reported on a single case of a patient with gastrointestinal symptoms. Read More

View Article and Full-Text PDF

Therapeutic options for CTLA-4 Insufficiency.

J Allergy Clin Immunol 2021 Jun 7. Epub 2021 Jun 7.

The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Background: Heterozygous germline mutations in cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) impair the immunomodulatory function of regulatory T cells. Affected individuals are prone to life-threatening autoimmune and lymphoproliferative complications. A number of therapeutic options are currently used with variable effectiveness. Read More

View Article and Full-Text PDF

Vaccination against COVID-19: a challenge in CLL.

Blood 2021 06;137(23):3153-3154

University of Cologne; Center for Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf.

View Article and Full-Text PDF

A case report of disseminated histoplasmosis in AIDS diagnosed through peripheral blood smear.

Curr HIV Res 2021 Jun 7. Epub 2021 Jun 7.

Infectious Diseases Unit, Fondazione IRCCS Policlinico San Matteo, Pavia. Italy.

Background: Histoplasma capsulatum is an environmental fungus that causes opportunistic infections in AIDS patients in endemic areas, but is uncommon in Europe. It shares clinical features with other opportunistic infections and lymphoproliferative disorders common in AIDS patients. The World Health Organization included Histoplasma antigen tests on the Lists of Essential In Vitro Diagnostics; however, they are not routinely available in non-endemic countries. Read More

View Article and Full-Text PDF

Unicentric Castleman's disease of hepatic hilum and retroperitoneum: a case report for endoscopic ultrasonography differential diagnosis and a literature review.

Clin J Gastroenterol 2021 Jun 10. Epub 2021 Jun 10.

Department of Gastroenterology, Affiliated Zhongda Hospital of Southeast University, Nanjing, China.

Castleman's disease (CD) is a highly heterogeneous clinico-pathological entity belonging to the lymphoproliferative disorders. CD can occur in any part of the human body where lymph nodes are present. In addition, very few cases have been reported in hepatic hilum. Read More

View Article and Full-Text PDF

[Molecular classification of aggressive B-cell lymphoma].

Authors:
Daisuke Ennishi

Rinsho Ketsueki 2021 ;62(5):418-423

Center for Comprehensive Genomic Medicine, Okayama University Hospital.

Diffuse large B-cell lymphoma (DLBCL) is a clinically and biologically highly heterogeneous disease; various molecular genetic abnormalities contribute to DLBCL development. In particular, recent advances in genomics technologies have led to the discovery of unknown genetic abnormalities and gene expression patterns. Based on the identified pathophysiologies, molecular sub-classification of DLBCL has been progressing. Read More

View Article and Full-Text PDF

[Current status and future prospects of immunotherapy for multiple myeloma].

Authors:
Yoichi Imai

Rinsho Ketsueki 2021 ;62(5):407-417

IMSUT Hospital, The Institute of Medical Science, The University of Tokyo.

The introduction of autologous stem cell transplantation, proteasome inhibitors, and immunomodulatory drugs (IMiDs) has improved the treatment outcome for multiple myeloma (MM). However, many patients develop resistance to existing therapies, and novel treatment strategies for these patients must be established. Therapeutic antibodies including daratumumab targeting CD38 and elotuzumab targeting SLAMF7 have been introduced in the clinic as immunotherapies for MM. Read More

View Article and Full-Text PDF

[Development and prospects of molecular targeted agents for malignant lymphoma].

Authors:
Wataru Munakata

Rinsho Ketsueki 2021 ;62(5):398-406

Department of Hematology, National Cancer Center Hospital.

It has been 20 years since the clinical introduction of rituximab, a monoclonal anti-CD20 antibody. Rituximab combination chemotherapy has substantially improved the prognosis of nearly all B-cell malignancies. Twenty years following the clinical introduction of rituximab, the era of molecular targeted agents and development of novel molecular targeted agents, including monoclonal antibody based on the molecular pathology, has been promoted. Read More

View Article and Full-Text PDF

[Allogeneic stem cell transplantation for aggressive NK cell leukemia].

Authors:
Ayumi Fujimoto

Rinsho Ketsueki 2021 ;62(5):360-368

Department of Hematology, Shimane University Hospital.

Aggressive NK cell leukemia (ANKL) is a rare leukemic form of mature NK cell neoplasms. ANKL presents a fulminant clinical course with a median overall survival (OS) of 2-3 months after diagnosis. Currently, allogeneic stem cell transplantation (allo-HSCT) is the only curative treatment for ANKL patients. Read More

View Article and Full-Text PDF

[Chronic-phase chronic myeloid leukemia with intracranial hemorrhage complicated with tumor lysis syndrome].

Rinsho Ketsueki 2021 ;62(5):346-351

Department of Hematology/Oncology, Saitama Children's Medical Center.

A 14-year-old male with autism was admitted to our hospital owing to altered consciousness and gait disturbance. Blood tests showed a white blood cell (WBC) count of 728,600/µl, and brain computed tomography revealed intracranial hemorrhage and a midline shift of the brain. The chronic phase of chronic myeloid leukemia (CML) was confirmed as per bone marrow aspiration findings. Read More

View Article and Full-Text PDF

[Primary breast diffuse large B-cell lymphoma in an elderly man maintaining long-term complete response].

Rinsho Ketsueki 2021 ;62(5):341-345

Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine.

Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare non-Hodgkin's lymphoma that mostly affects women. Here, we report a case of primary breast DLBCL that affected an older man without any autoimmune disease or drug-related female hormones. The patient was a 65-year-old man whose chief complaints were gradually-increasing lump in the right chest and swelling of the right axillary lymph nodes. Read More

View Article and Full-Text PDF

Case report of osteolytic lesions in a patient with multisystem granulomatous disease.

BMJ Case Rep 2021 Jun 9;14(6). Epub 2021 Jun 9.

School of Medicine, University of Notre Dame, Fremantle, Western Australia, Australia.

We present a case of a 70-year-old Caucasian woman with multisystem granulomatous disease involving her lungs, bones and lymph nodes. The patient initially presented with cervical lymphadenopathy and subsequently developed progressive breathlessness. Imaging revealed extensive mediastinal, hilar and intra-abdominal lymphadenopathy as well as bilateral pulmonary parenchymal infiltrates. Read More

View Article and Full-Text PDF

IMMUNE-MEDIATED INTRAOCULAR INFLAMMATION. A REVIEW.

Cesk Slov Oftalmol 2020 ;1(Ahead of print):1-6

Immune mediated inflammatory diseases are categorized into autoimmune and autoinflammatory. Autoimmune etiology is represented by autoreactive lymphocytes or autoantibodies, e.g. Read More

View Article and Full-Text PDF

[A Case of Pelvic Unicentric Castleman Disease Treated by Preoperative Transcatheter Arterial Embolization and Tumor Complete Resection with Combined Lower Abdominal and Posterior Approach].

Hinyokika Kiyo 2021 Apr;67(4):157-162

The Department of Urology, Kyoto University Hospital.

A 22-year-old woman was referred to our hospital for further examination of an incidentally discovered hypervascular pelvic tumor with a maximum diameter of 10 cm. Although Castleman disease was suspected based on the imaging findings and pathologic findings of the needle biopsy, a definitive diagnosis was not made. Preoperative transcatheter arterial embolization was performed to decrease intraoperative bleeding, and tumor resection was performed on the following day. Read More

View Article and Full-Text PDF

Diffuse Large B-Cell Lymphoma. Reply.

N Engl J Med 2021 06;384(23):2262

Memorial Sloan Kettering Cancer Center, New York, NY.

View Article and Full-Text PDF

Diffuse Large B-Cell Lymphoma.

N Engl J Med 2021 06;384(23):2261-2262

University of Calgary, Calgary, AB, Canada

View Article and Full-Text PDF

Specific features of T- and NK-cellular immunity in chronic lymphocytic leukemia.

Klin Lab Diagn 2021 Jun;66(6):345-352

Russian Medical Academy of professional continuous education.

Profound immunological dysfunction is the key factor determining the development of infectious complications in chronic lymphocytic leukemia (CLL). The aim of this work is to assess the features of the subpopulation composition of T-lymphocytes (T-helpers (Th), cytotoxic T-lymphocytes (Tcyt), T regulatory cells (Treg), T-NK cells, naive Th, Th-memory, activated T-lymphocytes, TCRγδ cells) and NK cells in peripheral blood of patients with newly diagnosed chronic lymphocytic leukemia (CLL) and receiving ibrutinib therapy. Hematological and immunophenotypic studies have been performed in 30 patients with previously untreated CLL, 122 patients on ibrutinib therapy and 20 healthy donors. Read More

View Article and Full-Text PDF

Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches.

Hematol Oncol 2021 Jun;39 Suppl 1:31-38

Department of Medicine III, LMU Hospital, Munich, Germany.

Mantle cell lymphoma (MCL) is clinically characterized by its heterogenous behavior with courses ranging from indolent cases that do not require therapy for years to highly aggressive MCL with very limited prognosis. A better understanding of the complex biology of MCL has already led to the approval of several innovative agents, expanding the landscape of MCL therapies and improving therapeutic options especially for refractory or relapsed disease. Nevertheless, to further optimize MCL treatment, early identification of individual risk profile and risk-adapted, patient-tailored choice of therapeutic strategy needs to be prospectively incorporated in clinical patient management. Read More

View Article and Full-Text PDF

Cutaneous T-cell lymphomas-An update 2021.

Hematol Oncol 2021 Jun;39 Suppl 1:46-51

Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany.

Cutaneous T-cell lymphomas (CTCL) represent the majority of primary cutaneous lymphomas (CL). Mycosis fungoides (MF) and cutaneous CD30+ lymphoproliferative disorders account for 80% of all CTCL. CTCL show overlapping histological features. Read More

View Article and Full-Text PDF

What's new in peripheral T-cell lymphomas.

Hematol Oncol 2021 Jun;39 Suppl 1:52-60

Surgical, Medical and Dental Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Reggio Emilia, Italy.

Peripheral T-cell lymphomas (PTCLs) are a rare, heterogeneous group of hematological malignancies with extremely poor prognosis for almost all subtypes. The diverse clinicopathological features of PTCLs make accurate diagnosis, prognosis, and choice of optimal treatment strategies difficult. Moreover, the best therapeutic algorithms are still under debate due to the extrapolated approaches developed for B-cell lymphomas and to the absence of few treatment protocol specifically developed for PTCLs. Read More

View Article and Full-Text PDF

Molecular classification of aggressive lymphomas-past, present, future.

Hematol Oncol 2021 Jun;39 Suppl 1:24-30

Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.

Aggressive large B-cell lymphomas (LBCLs) represent a frequent but clinically and molecularly heterogeneous group of tumors. Technological advances over the last decades prompted the development of different classification schemas to either sharpen diagnoses, dissect molecular heterogeneity, predict outcome, or identify rational treatment targets. Despite increased diagnostic precision and a noticeably improved molecular understanding of these lymphomas, clinical perspectives of patients largely remain unchanged. Read More

View Article and Full-Text PDF

Bispecific antibodies for the treatment of lymphomas: Promises and challenges.

Hematol Oncol 2021 Jun;39 Suppl 1:113-116

Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennyslvania, USA.

The potential of bispecific antibodies to direct antigen-specific T cell-mediated cytotoxicity toward malignant cells bearing a target antigen was recognized over 35 years ago. Generally, this is accomplished by combining a T-cell receptor-specific monoclonal antibody or monoclonal antibody-derived fragment that is capable of activating and expanding resting T cells with a second monoclonal antibody or monoclonal antibody fragment directed against a tumor target antigen. Bispecific antibodies induce effector T cells that bind to tumor cells independently of their T-cell receptor specificity and without the requirement of MHC-mediated antigen presentation, focusing effector T-cell cytotoxicity on tumor cells bearing the target antigen. Read More

View Article and Full-Text PDF

Optimizing CAR T cell therapy in lymphoma.

Hematol Oncol 2021 Jun;39 Suppl 1:104-112

Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Chimeric antigen receptor (CAR) T cell therapy has significantly improved the outlook for patients with certain types of poor-risk lymphoma. Despite these advances, a majority of patients undergoing CAR T therapy will suffer progression or relapse of disease, and toxicity remains a concern. Additionally, the patients and disease subtypes that are most likely to benefit from CAR T have yet to be fully defined. Read More

View Article and Full-Text PDF

Vulnerabilities in the tumor and microenvironment in follicular lymphoma.

Hematol Oncol 2021 Jun;39 Suppl 1:83-87

Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.

Follicular lymphoma (FL) is a paradigm of tumors that require the interaction between tumor and microenvironment cells to foster their development from initial steps to progression. Recent large-scale genome studies have uncovered multiple genetic alterations of FL that influence the microenvironment in two main directions, promoting tumor cell survival and proliferation and facilitating their evasion from immune antitumor signals. Understanding the crosstalk between tumor B-cells and the microenvironment will facilitate the identification of vulnerabilities that may offer novel targets for treatment of the patients. Read More

View Article and Full-Text PDF

Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cure.

Hematol Oncol 2021 Jun;39 Suppl 1:39-45

Centre for Cancer Immunology, CRUK Research Centre, University of Southampton, Southampton, UK.

The treatment of classical Hodgkin lymphoma in young patients is one of the success stories of modern medicine. The use of risk- and response-adapted approaches to guide treatment decisions has led to impressive cure rates while reducing the long-term toxicity associated with more intensive therapies. Tissue biomarkers have not yet proven more effective than clinical characteristics for risk stratification of patients at presentation, but functional imaging features such as metabolic tumor volume may be used to predict response, if early observations can be validated. Read More

View Article and Full-Text PDF

Allogeneic stem cell transplant in non-Hodgkin lymphomas: Still an indication?

Authors:
Peter Dreger

Hematol Oncol 2021 Jun;39 Suppl 1:100-103

Department of Medicine V, University of Heidelberg, Heidelberg, Germany.

Allogeneic hematopoietic cell transplantation (alloHCT) used to play a defined role in the treatment of non-Hodgkin lymphoma (NHL). With the advent of modern targeted molecular therapies and immunotherapies, treatment standards at least for B-cell lymphoma have undergone significant changes, thereby questioning the traditional role of alloHCT in these diseases. This paper attempts to describe the current place and the perspectives of alloHCT in the rapidly evolving treatment landscape of NHL. Read More

View Article and Full-Text PDF

High-risk follicular lymphoma: Treatment options.

Authors:
Brad Kahl

Hematol Oncol 2021 Jun;39 Suppl 1:94-99

Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the Western hemisphere. The natural history of FL appears to have been favorably impacted by the introduction of rituximab. Randomized clinical trials have demonstrated that the addition of rituximab to standard chemotherapy induction has improved the overall survival. Read More

View Article and Full-Text PDF

Upfront identification of high-risk follicular lymphoma.

Authors:
Carla Casulo

Hematol Oncol 2021 Jun;39 Suppl 1:88-93

Department of Medicine, Division of Hematology and Oncology, Wilmot Cancer Institute, Rochester, New York, USA.

Follicular lymphoma (FL) is a common disease with clinically indolent behavior, and a long natural history for the majority of patients. Despite excellent therapeutic strategies currently available for FL, approximately 10%-20% of patients will experience early disease progression, defined as occurring within two years of diagnosis. These patients have poor outcomes, with overall survival at 5 years ranging between 37% and 50%. Read More

View Article and Full-Text PDF